Slc12a8 is a nicotinamide mononucleotide transporter

Plain-language summary

Published 2019 in Nature Metabolism, this work by Grozio A and collaborators tackles a specific question within science-focused NMN/NAD+ research.

Key findings reported by the authors

• Identified Slc12a8 as putative direct NMN transporter in mice
• Controversial - disputed by Schmidt & Brenner 2019
• Important context for sublingual vs oral debate

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to science decisions. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

Where we cite this paper

• How NMN Works: The Complete Guide to NAD+ Biology
• NMN vs NR Mechanism: Why Both Reach NAD+ But Differently